Home Visit
Upload
NextGen Oncomine Focus 52 Gene Panel
Also known as: NextGen : Oncomine Focus Array Panel (52 Gene), Tissue
No special precautions
Recommended for
Male, Female
Report
Within 4 Weeks
Blood test at Home
NABL & CAP Accredited Labs
Accurate & Quality Test Reports
Trusted by Leading Doctors & Hospitals
Overview
NextGen Oncomine Focus panel is a single panel for testing 1000 variants across 52 genes in solid tumors. The panel uses next generation sequencing for concurrent analysis of DNA and RNA including hotspots, single-nucleotide variants (SNVs), indels, copy number variants (CNVs), and gene fusions, in a single workflow to screen for relevant, drug able mutations and fusions in the cancer genesThis test is effective in identifying drug responsive targets in various cancers.
Histopath report mandatory.
NextGen : Oncomine Focus Array Panel (52 Gene), Tissue Price
Metropolis Healthcare is a leading diagnostics centre and pathology lab in India equipped with the latest state-of-the-art technologies that provides the NextGen : Oncomine Focus Array Panel (52 Gene), Tissue with a clear pricing structure.
The NextGen : Oncomine Focus Array Panel (52 Gene), Tissue Price in Rajkot is ₹ 39,500 .
We are committed to deliver accurate and quality results from the best labs in India with complete transparency regarding test cost and turnaround time. No matter where you are, we strive to offer patients high-quality service that is affordable and accessible.
Frequently Asked Questions
The test identifies the 52 drug responsive actionable genes using the Next generation sequencing (NGS) sequencing.
- This panel is used for the screening of relevant, drug able mutations and fusions for various Cancers.
- The panel analyses 1000 variants across 52 genes for cancers.
• The test is advisable for tumour where first line treatment depends upon molecular testing i.e., lung, colorectal and melanoma.
- For rare cancers like biliary tract, sarcomas, mesothelioma and cancers with unknow primary.
- Those patients in whom the 1st or 2nd line of therapy has failed, to help identify alternative targeted therapies.
- The panel is a focused panel recommended for cancer patients to decide the targeted therapy based on the fusion or mutated genes detected.
An FFPE block with at least 10% tumor content is required as a sample.
No special precautions.
Results show the drug responsive status in the 52 identifiable cancer genes and its subsequent mutations and fusions. Based on the results the oncologist decides the further line of targeted therapy. Please consult the clinician for further clinical correlation and outcomes.
- Oncomine Focus Test
- NextGen Oncomine Test
- Focus 52 gene panel.
Ratings & Reviews (0)
Why Metropolis?
Metropolis has a team of 200 senior pathologists and over 2000 technicians delivering diagnostic solutions in the areas of routine, semi specialty and super specialty domains like Oncology, Neurology, Gynaecology, Nephrology and many more.
We offer a comprehensive range of 4000+ clinical laboratory tests and profiles, which are used for prediction, early detection, diagnostic screening, confirmation and/or monitoring of the disease.
WhatsApp